Bioventus said today it entered the Taiwanese patient care market with the launch of its Durolane single-injection joint-fluid osteoarthritis treatment. The treatment is based around the NASHA process which produces stabilized hyaluronic acid which provides lubrication and cushioning in a normal joint. “The combination of a leading OA solution like Durolane and Taiwan’s robust economy gives Bioventus […]
Regenerative Medicine
Exactech deals dental assets to Salvin Dental Specialties
Exactech (NSDQ:EXAC) said today it sold the entirety of its dental biologics business to Salvin Dental Specialties, through its Salvin Regenerative subsidiary. Financial terms and other details of the deal were not disclosed. Salvin Dental develops, manufactures and markets implant dentistry regenerative biomaterials and surgical instrumentation, Exactech said. “While it has been a pleasure to […]
Gore touts bioabsorbable hernia mesh study data
W.L. Gore & Associates today released data from a long-term study of its Gore Bio-A tissue reinforcement bioabsorbable mesh designed to treat complex ventral hernias in patients with contaminated fields. The study was published in the Annals of Surgery. Gore’s Bio-A is designed as a web of biocompatible synthetic polymers that are gradually reabsorbed into […]
InVivo Therapeutics wins FDA approval for pivotal trial of spinal scaffold
InVivo Therapeutics (NSDQ:NVIV) said today that it won FDA approval to shift a pilot trial of its spinal scaffold to a pivotal probable benefit study. Cambridge, Mass.-based InVivo said it expects the FDA to OK its Inspire study, designed to enroll 20 patients with spinal cord injuries, after it submits 6-month data during the 2nd quarter […]
MiMedx revives Organogenesis beef
MiMedx (NSDQ:MDXG) CEO Pete Petit last week renewed a beef with regenerative medicine rival Organogenesis, accusing that company of being behind a short-seller’s letter advising investors to bet against MiMedx. Early this year, Marietta, Ga.-based MiMedx bailed out of a lawsuit against Canton, Mass.-based Organogenesis alleging “malicious actions” and interference from Organogenesis in the U.S. Veterans Affairs Dept. decision to stop using its […]
InVivo looks to blaze ‘Bioengineered Neural Trails’ in spinal cord injury treatment
InVivo Therapeutics (NSDQ:NVIV) said today it is looking to ‘Bioengineered Neural Trails’, injectable biomaterial and neural stem mixtures, to help treat chronic spinal cord injuries. The Cambridge, Mass.-based company said it will focus its research efforts on the new therapy, and has inked agreements with the University of California, UC San Diego and Dr. James Guest […]
StemCells says spinal injury therapy shows promise
(Reuters) — StemCells Inc said its experimental stem cell therapy improved the functioning and strength of limbs in patients with spinal cord injuries, becoming the second company to report promising data on the treatment for such injuries. The biotech company said interim results from the mid-stage study showed 4 of 6 patients experienced an improvement on 2 different scales. […]
Integra LifeSciences boosts outlook
Integra LifeSciences (NSDQ:IART) yesterday raised its long-term forecast out to 2018, saying it expects to post higher numbers across the board. The new outlook calls for adjusted earnings-per-share growth of 12% or more, up from 10% previously, on organic sales growth of 6% to 8%, up from prior guidance of 5% to 7%. Gross margins […]
HART targets artificial bronchus, esophagus for turnaround
Jim McGorry, CEO of Harvard Apparatus Regenerative Technology (NSDQ:HART), said he’s ready to right the ship at HART by expanding its regenerative trachea tech into both the bronchus and esophagus. McGorry has been the CEO of HART for 4 months, and told the Boston Business Journal he’s preparing to turn the company’s stock slide around. The reins were […]
LoneStar Heart touts 1-year Algisyl data
LoneStar Heart yesterday presented 1-year data from a follow-up study of its Algisyl hydrogel cardiac implant designed to treat patients with failing heart muscle. The presentation was made at the American Heart Association’s annual meeting in Orlando and published in the European Journal of Heart Failure. Algisyl is a novel inert hydrogel that is designed to be […]
Derma Sciences scraps trial, mulls sale
Derma Sciences (NSDQ:DSCI) said today it would evaluate all options, including a sale, after scrapping a trial of its aclerastide drug for diabetic foot ulcers. DSCI shares plunged as much as 31%, dropping under their 6-year low today. The company makes wound care and regenerative medicine products. Aclerastide was its only drug candidate. Princeton, N.J.-based Derma Sciences said […]